Capsida Biotherapeutics Announces Executive Appointments

• Capsida Biotherapeutics appointed Swati Toleas as the company’s first Chief Medical Officer. Swati comes from Genentech where she spent 13 years in roles of increasing responsibility, most recently as Vice President of Clinical Development.

• Rita Balice-Gordon has joined the Board of Directors. Rita has served as the Chief Scientific Officer of Muna Therapeutics since May 2020 and is an Entrepreneur-in-Residence at Novo Seeds since August 2020. Previously, she served in scientific roles of increasing responsibility at Sanofi, most recently as Global Head of Rare and Neurological Diseases.

Capsida Biotherapeutics is a privately held biotechnology company based in Newbury Park, CA engineering novel AAVs and developing the next generation of gene therapies. It employs approximately 55 people.